

Losartan Formulation

| Vers 3.3 | sion | Revision Date: 23.03.2020 | | S Number: 353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 |
|-------------|---|------------------------------|------|-------------------------------------|---|
| 1. PI | RODUC | CT AND COMPANY IDI | ENT | IFICATION | |
| | Product name | | : | Losartan Formulation | |
| | Manuf | acturer or supplier's c | leta | ils | |
| | Compa | any | : | Organon & Co. | |
| | Addres | S | : | 30 Hudson Stree Jersey City, New | et, 33nd floor / Jersey, U.S.A 07302 |
| | Teleph | one | : | 551-430-6000 | |
| | Emergency telephone number | | • : | 215-631-6999 | |
| | E-mail | address | : | EHSSTEWARD | @organon.com |
| | Recommended use of the chemical and restrictions on use | | | | ons on use |
| | Recom | mended use | : | Pharmaceutical | |
| 2. H | AZARD | S IDENTIFICATION | | | |

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

| GHS Classification | |
|-----------------------|--|
| Acute toxicity (Oral) | |

| Acute toxicity (Oral) | : | Category 4 |
|---|---|---|
| Serious eye damage/eye irri- tation | : | Category 1 |
| Skin sensitisation | : | Category 1 |
| Reproductive toxicity | : | Category 1B |
| Effects on or via lactation | | |
| Specific target organ toxicity - repeated exposure (Oral) | : | Category 2 (Blood, Cardio-vascular system, Stomach, Kidney) |
| GHS label elements | | |
| Hazard pictograms | : | |
| Signal word | : | Danger |
| Hazard statements | : | H302 Harmful if swallowed. H317 May cause an allergic skin reaction. |



Losartan Formulation

| ersion 3 | Revision Date: 23.03.2020 | SDS Number: 19353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 |
|-------------|---------------------------|--|---|
| | | H360D May d H362 May ca H373 May ca | serious eye damage. amage the unborn child. use harm to breast-fed children. use damage to organs (Blood, Cardio-vascular ach, Kidney) through prolonged or repeated ex- lowed. |
| Preca | utionary statements | P202 Do not I and understoo P260 Do not I P263 Avoid of P264 Wash s P270 Do not e P272 Contam the workplace | preathe dust. ontact during pregnancy and while nursing. kin thoroughly after handling. eat, drink or smoke when using this product. inated work clothing should not be allowed out s. rotective gloves/ protective clothing/ eye protec- |
| | | CENTER/ doc P302 + P352 P305 + P351 water for seve and easy to d CENTER/ doc P308 + P313 attention. P333 + P313 vice/ attention | IF exposed or concerned: Get medical advice/ If skin irritation or rash occurs: Get medical ad- |
| | | Storage: P405 Store lo | cked up. |
| | | Disposal: P501 Dispose disposal plant | e of contents/ container to an approved waste |

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|---------------|-----------|--------------------------|
| Cellulose | 9004-34-6 | >= 30 - < 50 |



Losartan Formulation

| Version 3.3 | Revision Date: 23.03.2020 | SDS Number: 19353-00016 | Date of last issue: 13.0 Date of first issue: 07.1 | |
|----------------|--|---|---|---------------------|
| Losa | rtan | | 124750-99-8 | >= 30 - < 50 |
| Starc | h | | 9005-25-8 | >= 10 - < 20 |
| . FIRST | AID MEASURES | | | |
| Gene | eral advice | vice immediate | accident or if you feel unwe ely. ns persist or in all cases of | |
| lf inha | aled | : If inhaled, rem Get medical at | ove to fresh air. tention. | |
| In ca | se of skin contact | of water. Remove conta Get medical at Wash clothing | | |
| In ca | se of eye contact | : In case of con for at least 15 If easy to do, r | tact, immediately flush eyes | |
| lf swa | allowed | : If swallowed, I Get medical at Rinse mouth tl | DO NOT induce vomiting. | nscious person. |
| | important symptoms effects, both acute and red | : Harmful if swa May cause an Causes seriou May damage t May cause ha May cause da exposure if sw | llowed. allergic skin reaction. s eye damage. he unborn child. rm to breast-fed children. mage to organs through pro | olonged or repeated |
| Prote | ection of first-aiders | : First Aid respo and use the re | nders should pay attention commended personal prote ntial for exposure exists (se | ective equipment |
| Notes | s to physician | | natically and supportively. | |

Suitable extinguishing media : Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical None known. Unsuitable extinguishing : media Specific hazards during fire-: Avoid generating dust; fine dust dispersed in air in sufficient fighting concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health. Hazardous combustion prod- : Carbon oxides ucts Chlorine compounds



Losartan Formulation

| Version 3.3 | Revision Date: 23.03.2020 | | S Number: 353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 |
|----------------|--|-----|--|--|
| | | | Nitrogen oxides (I | NOx) |
| Speci ods | fic extinguishing meth- | : | cumstances and t Use water spray t Remove undama so. | measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do |
| | al protective equipment efighters | : | | e, wear self-contained breathing apparatus. ective equipment. |
| 6. ACCIDI | ENTAL RELEASE MEAS | SUF | RES | |
| tive e | nal precautions, protec- quipment and emer- procedures | : | | ective equipment. ing advice and personal protective equip- ations. |
| Envir | onmental precautions | : | Prevent further le Retain and dispos | e environment must be avoided. akage or spillage if safe to do so. se of contaminated wash water. should be advised if significant spillages ed. |
| | ods and materials for inment and cleaning up | : | tainer for disposa Avoid dispersal of with compressed Dust deposits sho es, as these may leased into the att Local or national posal of this mate employed in the of mine which regula Sections 13 and 1 | dust in the air (i.e., clearing dust surfaces |

7. HANDLING AND STORAGE

| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
|-------------------------|---|---|
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Minimize dust generation and accumulation. |



| Version 3.3 | Revision Date: 23.03.2020 | SDS Number: 19353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 | | |
|-----------------------------|---------------------------|--|--|--|--|
| | | Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to environment. | | | |
| Conditions for safe storage | | : Keep in properly labelled containers. Store locked up. Keep tightly closed. | | | |
| Mater | rials to avoid | | dance with the particular national regulations. ith the following product types: ng agents | | |

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parame- ters / Permissible concentration | Basis |
|------------|-------------|-------------------------------------|--|----------|
| Cellulose | 9004-34-6 | TWA | 10 mg/m3 | ACGIH |
| Losartan | 124750-99-8 | TWA | 100 µg/m3 (OEB 2) | Internal |
| Starch | 9005-25-8 | TWA | 10 mg/m3 | ACGIH |

| Engineering measures : | Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are de- signed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust ventilation. |
|----------------------------------|--|
| Personal protective equipmen | t i i i i i i i i i i i i i i i i i i i |
| Respiratory protection : | If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. |
| Filter type : Hand protection | Particulates type |
| Material : | Chemical-resistant gloves |
| Remarks : | Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous sub- stance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday. |
| Eye protection : | Wear the following personal protective equipment: Chemical resistant goggles must be worn. If splashes are likely to occur, wear: Face-shield |



Losartan Formulation

| Version 3.3 | Revision Date: 23.03.2020 | SDS Number: 19353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 |
|----------------|---------------------------|--|--|
| | nd body protection | sistance data and tial. Skin contact mus clothing (gloves, : If exposure to ch | e protective clothing based on chemical re- d an assessment of the local exposure poten- at be avoided by using impervious protective aprons, boots, etc). emical is likely during typical use, provide eye and safety showers close to the working |
| | | | ot eat, drink or smoke. ted clothing before re-use. |

9. PHYSICAL AND CHEMICAL PROPERTIES

| Appearance | : | powder |
|---|---|--|
| Colour | : | White to light yellow |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| рН | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | No data available |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, han- dling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | No data available |
| Relative vapour density | : | No data available |
| Relative density | : | No data available |
| Density | : | 1 g/cm3 |
| Solubility(ies) Water solubility | : | No data available |
| Partition coefficient: n- | : | No data available |



Losartan Formulation

| Vers 3.3 | sion | Revision Date: 23.03.2020 | - | 0S Number: 353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 | |
|-------------|------------------|---|---|---|---|--|
| | octano | l/water | | | | |
| | Auto-iç | nition temperature | : | No data available | 3 | |
| | Decom | position temperature | : | No data available |) | |
| | Viscos | 1 | | | | |
| | VIS | cosity, kinematic | : | No data available | | |
| | Explos | ive properties | : | Not explosive | | |
| | Oxidizi | ng properties | : | The substance o | r mixture is not classified as oxidizing. | |
| | Molecu | ular weight | : | No data available | 3 | |
| | Minimu | um ignition energy | : | > 300 mJ | | |
| | Particle | e size | : | No data available | | |
| 10. | STABIL | ITY AND REACTIVITY | (| | | |
| | | vity cal stability ility of hazardous reac- | : | Stable under nor May form explosi dling or other me | ve dust-air mixture during processing, han- | |
| | Condit | ions to avoid | : | Heat, flames and | | |
| | | batible materials dous decomposition sts | : | Avoid dust formation.Oxidizing agentsNo hazardous decomposition products are known. | | |
| 11. | тохісо | | | N | | |
| | Inform exposi | ation on likely routes of ure | : | Inhalation Skin contact Ingestion Eye contact | | |
| | | toxicity Il if swallowed. | | | | |
| | <u>Produ</u> | <u>ct:</u> | | | | |
| | Acute | oral toxicity | : | Acute toxicity esti Method: Calculati | mate: 1,502 mg/kg on method | |
| | <u>Comp</u> | onents: | | | | |
| | Cellul | ose: | | | | |
| | Acute | oral toxicity | : | LD50 (Rat): > 5,0 | 00 mg/kg | |
| | Acute | inhalation toxicity | : | LC50 (Rat): > 5.8 Exposure time: 4 | | |
| | | | | | | |



Losartan Formulation

| rsion | Revision Date: 23.03.2020 | SDS Number:Date of last issue: 13.09.201919353-00016Date of first issue: 07.10.2014 |
|--|--|---|
| | | Test atmosphere: dust/mist |
| Acute | e dermal toxicity | : LD50 (Rabbit): > 2,000 mg/kg |
| Losa | rtan: | |
| Acute | e oral toxicity | : LD50 (Mouse): 1,257 - 1,590 mg/kg |
| | | LDLo (Rat): 200 mg/kg |
| | | LDLo (Mouse): 400 mg/kg |
| Starc | h: | |
| Acute | e oral toxicity | : LD50 (Rat): > 5,000 mg/kg |
| Acute | e dermal toxicity | : LD50 (Rabbit): > 2,000 mg/kg |
| Not c | corrosion/irritation lassified based on ava | ailable information. |
| | ponents: | |
| Losa Speci | | : Rabbit |
| Resu | | : Mild skin irritation |
| | ous eye damage/eye es serious eye damag | |
| <u>Com</u> | ponents: | |
| Losa | rtan: | |
| Speci Resul | | : Rabbit : Severe irritation |
| Resu | it. | |
| Starc | | |
| Speci Resu | | : Rabbit : No eye irritation |
| i tesu | it. | |
| Resp | iratory or skin sensi | tisation |
| | | |
| | sensitisation | |
| May o | cause an allergic skin | |
| May o Resp | cause an allergic skin iratory sensitisation | |
| May o Resp Not cl | cause an allergic skin iratory sensitisation lassified based on ava | |
| May o Resp Not cl <u>Com</u> | cause an allergic skin iratory sensitisation lassified based on ava ponents: | |
| May o Resp Not cl <u>Com</u> | cause an allergic skin iratory sensitisation lassified based on ava ponents: rtan: | ailable information. |
| May of Resp Not cl Comp Losa | cause an allergic skin iratory sensitisation lassified based on ava ponents: rtan: | |



| Version 3.3 | Revision Date: 23.03.2020 | - | S Number: 353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 |
|----------------------|---|---------|--|--|
| Asse Resu | ssment It | : | Probability or positive | evidence of skin sensitisation in humans |
| Test Expo Spec | Starch: Test Type Exposure routes Species Result | | Maximisation Skin contact Guinea pig negative | Test |
| | n cell mutagenicity lassified based on ava | ailable | information. | |
| | ponents: | | | |
| | llose: otoxicity in vitro | : | Test Type: Ba Result: negati | cterial reverse mutation assay (AMES) ve |
| | | | Test Type: In Result: negati | vitro mammalian cell gene mutation test ve |
| Genc | otoxicity in vivo | : | cytogenetic as Species: Mou | se Dute: Ingestion |
| Losa | rtan: | | | |
| Genc | otoxicity in vitro | : | Test Type: in Result: negati | |
| | | | | vitro mammalian cell gene mutation test Chinese hamster ovary cells ve |
| | | | Test Type: All Result: negati | caline elution assay ve |
| | | | Test Type: Ch Result: negati | romosomal aberration ve |
| Genc | otoxicity in vivo | : | Test Type: Ch Result: negati | romosomal aberration ve |
| Stard | sh: | | | |
| Geno | otoxicity in vitro | : | Test Type: Ba Result: negati | cterial reverse mutation assay (AMES) ve |

Carcinogenicity

Not classified based on available information.



| Version 3.3 | Revision Date: 23.03.2020 | SDS Number: 19353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 |
|----------------|---|---|---|
| <u>Co</u> | mponents: | | |
| Ce | llulose: | | |
| Spe | ecies | : Rat | |
| • | olication Route | : Ingestion | |
| | posure time | : 72 weeks | |
| Re | sult | : negative | |
| Lo | sartan: | | |
| Spe | ecies | : Mouse | |
| • | olication Route | : Oral | |
| Exp | oosure time | : 92 weeks | |
| Do | se | : 200 mg/kg body | weight |
| Re | sult | : negative | |
| | ecies | : Rat | |
| | olication Route | : Oral | |
| | oosure time | : 105 weeks | |
| Do | se sult | : 270 mg/kg body : negative | weight |
| | Sur | . negative | |
| Re | productive toxicity | | |
| | y damage the unborn child y cause harm to breast-fec | | |
| | mponents: | | |
| Ce | llulose: | | |
| Effe | ects on fertility | : Test Type: One-o Species: Rat Application Route Result: negative | generation reproduction toxicity study e: Ingestion |
| Effe me | ects on foetal develop- nt | : Test Type: Fertili Species: Rat Application Route | ty/early embryonic development |
| | | Result: negative | |
| Lo | sartan: | | |
| Effe | ects on fertility | Result: female re | nale |
| Effe me | ects on foetal develop- nt | Developmental T Result: Embryoto | |



Losartan Formulation

Exposure time

Application Route

Exposure time

Symptoms

Species

Target Organs

Species

NOAEL

Number of exposures

| /ersion 3.3 | Revision Date: 23.03.2020 | SDS Number: 19353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 |
|----------------|--|---|---|
| | | teratogenic | effects |
| | | Species: Ra Application Developme | Development at Route: Oral ntal Toxicity: LOAEL: 10 mg/kg body weight otoxicity, No teratogenic effects |
| | Reproductive toxicity - As- : sessment | | nce of adverse effects on development, based on eriments. |
| | | Studies ind od | icating a hazard to babies during the lactation per |
| | - single exposure assified based on avai | able information. | |
| May o | - repeated exposure cause damage to organ d or repeated exposure | | vascular system, Stomach, Kidney) through pro- |
| <u>Com</u> | oonents: | | |
| Targe | r tan: sure routes et Organs ssment | | lio-vascular system, Stomach, Kidney damage to organs through prolonged or repeated |
| Repe | ated dose toxicity | | |
| <u>Com</u> | oonents: | | |
| Cellu | lose: | | |
| | | : Rat : >= 9,000 m : Ingestion : 90 Days | g/kg |
| Losa | rtan: | | |
| | | : Rat : 15 mg/kg : Oral | |

Salivation, Vomiting

Blood, Kidney, Cardio-vascular system, Stomach

: 309 d

5 mg/kg

1 Months

Oral

: daily

:

: Dog

:

:

:

:

: Dog





| Versior 3.3 | Revision Date: 23.03.2020 | SDS Number: 19353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 |
|----------------------|--|--|--|
| Ap Ex Nu | DAEL plication Route posure time Imber of exposures mptoms | : 25 mg/kg : Oral : 53 Weeks : daily : Salivation, Voi | niting |
| Sp NC Ap Ex | arch: ecies DAEL plication Route posure time ethod | : Rat : >= 2,000 mg/k : Skin contact : 28 Days : OECD Test G | - |
| | piration toxicity of classified based on availa | ble information. | |
| <u>Cc</u> | omponents: | | |
| - | sartan: aspiration toxicity classific | ation | |
| Ex | perience with human exp | osure | |
| <u>Cc</u> | omponents: | | |
| Ey | sartan: e contact gestion | : Symptoms: Ey : Symptoms: hy | re irritation potension, tachycardia |
| 12. EC | OLOGICAL INFORMATION | N | |
| | | | |
| Ec | otoxicity | | |
| <u>Cc</u> | omponents: | | |
| Ce | llulose: | | |
| То | xicity to fish | Exposure time | latipes (Japanese medaka)): > 100 mg/l :: 48 h ed on data from similar materials |
| Lo | sartan: | | |
| То | xicity to fish | : LC50 (Oncorh Exposure time Method: FDA | |
| | xicity to daphnia and other uatic invertebrates | Exposure time | a magna (Water flea)): 331 mg/l :: 48 h D Test Guideline 202 |
| | xicity to algae/aquatic ants | : NOEC (Micro Exposure time Method: FDA | |



Losartan Formulation

| ersion 3 | Revision Date: 23.03.2020 | - | OS Number: 353-00016 | Date of last issue: 13.09.2019 Date of first issue: 07.10.2014 |
|-----------------|---------------------------------|----|--|---|
| | | | NOEC (Selenast Exposure time: 1 Method: FDA 4.0 | |
| Toxic icity) | ity to fish (Chronic tox- | : | Exposure time: 33 Species: Pimepha | 2 d ales promelas (fathead minnow) est Guideline 210 |
| | ic invertebrates (Chron- | : | Exposure time: 2 Species: Daphnia | 1 d a magna (Water flea) est Guideline 211 |
| Persi | stence and degradabili | ty | | |
| <u>Com</u> | oonents: | | | |
| Cellu | lose: | | | |
| Biode | gradability | : | Result: Readily b | iodegradable. |
| Losa | rtan: | | | |
| Stabil | ity in water | : | Hydrolysis: < 10 9 | %(5 d) |
| Bioad | cumulative potential | | | |
| <u>Com</u> | oonents: | | | |
| Losa | rtan: | | | |
| | ion coefficient: n- ol/water | : | log Pow: 1.2 | |
| | lity in soil | | | |
| | ata available | | | |
| | r adverse effects | | | |
| No da | ata available | | | |

| Disposal i | methods |
|------------|---------|
|------------|---------|

| Waste from residues Contaminated packaging | | Dispose of in accordance with local regulations. Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |
|---|--|--|
|---|--|--|

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good



| Version | Revision Date: 23.03.2020 | SDS Number: | Date of last issue: 13.09.2019 |
|---------|---------------------------|-------------|---------------------------------|
| 3.3 | | 19353-00016 | Date of first issue: 07.10.2014 |
| | | | |

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

| AICS | : | not determined |
|-------|---|----------------|
| DSL | : | not determined |
| IECSC | : | not determined |

16. OTHER INFORMATION

Further information

| Sources of key data used to compile the Safety Data Sheet | : | Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/ | | |
|---|---|--|--|--|
| Date format | : | dd.mm.yyyy | | |
| Full text of other abbreviations | | | | |
| ACGIH | : | USA. ACGIH Threshold Limit Values (TLV) | | |
| ACGIH / TWA | : | 8-hour, time-weighted average | | |

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect



Losartan Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 13.09.2019 |
|---------|----------------|-------------|---------------------------------|
| 3.3 | 23.03.2020 | 19353-00016 | Date of first issue: 07.10.2014 |

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN